New Releases

Premium

Agendia last month launched BluePrint, an 80-gene signature breast cancer diagnostic that identifies the basal-like, luminal-like, and HER2 molecular subtypes in breast cancer tumors.

“Using BluePrint, we will research potentially different responses of therapies to biologically different subgroups together with our customers," Agendia Chief Medical Officer Richard Bender said in a statement. "In the future, we envision the clinical utility of a combination of BluePrint with MammaPrint’s original 70-gene panel."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.